A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control

Urology Case Reports 2026 Open access

Read full text
Authors: Saki Inaba, Toshiki Kijima, Mina Takaoka, Toshitaka Uematsu, Kohei Takei, Masahiro Yashi, Kazuyuki Ishida, Taku Aoki, Takao Kamai
DOI: 10.1016/j.eucr.2025.103337
Cited by: 1
References: 13

Abstract

Primary renal neuroendocrine tumor (NET) is extremely rare, with no established treatment for advanced cases. We report high-grade (G3) renal NET effectively treated with peptide receptor radionuclide therapy (PRRT). A 30-year-old man was diagnosed with primary renal NET G3 with liver metastases. After everolimus failure, he received 177Lu-DOTATATE (Lutathera®). Although the tumor continued growing after the first cycle, disease stabilized from the second cycle onwards. Stable disease was maintained for 12 months without severe adverse events, preserving quality of life. 177Lu-PRRT is a promising therapeutic option for high-grade, somatostatin receptor-positive renal NET when other treatments fail.

Fields of Study & Subjects

Neuroendocrine Tumor Research Advances Renal cell carcinoma treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Urology Case Reports
Publisher
Elsevier BV
Volume
65
Pages
103337–103337
Publication date
1 January 2026
Language
EN